Michael Sailor
Fundador en Impilo Therapeutics, Inc. .
Perfil
Michael Sailor is the founder of Impilo Therapeutics, Inc. He currently holds a position as Director at Cend Therapeutics, Inc.
Cargos activos de Michael Sailor
Empresas | Cargo | Inicio |
---|---|---|
Impilo Therapeutics, Inc.
Impilo Therapeutics, Inc. Packaged SoftwareTechnology Services Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA. | Fundador | - |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Director/Miembro de la Junta | 21/09/2020 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Impilo Therapeutics, Inc.
Impilo Therapeutics, Inc. Packaged SoftwareTechnology Services Impilo Therapeutics, Inc. engages in the development of platform for delivering nucleic acid-based medicines to solid tumor cancers. The company was founded by Sangeeta N. Bhatia, Frank J. Slack, and Michael Sailor and is headquartered in San Diego, CA. | Technology Services |
Cend Therapeutics, Inc.
Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Sailor